Omalizumab for the treatment of severe persistent allergic asthma in children aged 6–11

This is an extract from the guidance. The complete guidance is available at guidance.nice.org.uk/ta201

Important information about this guidance

This guidance has been updated and replaced by NICE technology appraisal guidance 278.